WilmerHale Advises Werewolf Therapeutics in $72M Series B Financing

  • 1.8.2021

On January 7, 2021, Werewolf Therapeutics, an oncology biotherapeutics company advancing a of next-generation, transformative cancer treatments, announced the completion of its $72 million Series B financing. The proceeds will advance Werewolf’s lead INDUKINE™ product candidates, WTX-124 (interleukin-2, or IL-2) and WTX-330 (interleukin-12, or IL-12) through Phase 1 clinical proof-of-concept studies, and progress additional programs to Investigational New Drug application-readiness. The financing was led by RA Capital Management and joined by new investors Deerfield Management, HBM Healthcare Investments, Soleus Capital, Adage Capital, Sphera Healthcare and CaaS Capital. Also participating in the financing were Werewolf’s Series A investors including MPM Capital, Longwood Fund, Taiho Ventures, Arkin Bio Ventures, UPMC Enterprises and DC Investment Partners.

The WilmerHale team representing Werewolf Therapeutics was led by Rosemary Reilly and included Michael Lopes and Abena Ababio.